A Prospective, Single-Arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Breast cancer; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 27 Dec 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003989).
- 16 Feb 2010 Actual patient number (411) added as reported by ClinicalTrials.gov.